S-1/A: Synergy CHC Corp Eyes Nasdaq Listing with $20 Million Public Offering

Synergy CHC Corp is planning a public offering of 2,000,000 shares of common stock, aiming for a Nasdaq listing and growth initiatives.

Summary

• Synergy CHC Corp is undertaking an S-1/A filing for a proposed public offering.
• The company intends to offer 2,000,000 shares of its common stock to the public.
• The estimated initial public offering price is projected to be between $9.00 and $11.00 per share.
• Synergy CHC Corp has applied to list its common stock on the Nasdaq Capital Market under the ticker symbol SNYR.
• The company's two marquee brands are FOCUSfactor and Flat Tummy.
• FOCUSfactor represented 85% of net revenue and Flat Tummy represented 15% for the six months ended June 30, 2024.
• Net revenue for the six months ended June 30, 2024, was $17.4 million, a 7.0% decrease compared to the same period in 2023.
• The company intends to use the net proceeds from the offering for general corporate purposes and to accelerate the growth of its FOCUSfactor supplements and energy RTD products.
• Roth Capital Partners is acting as the sole book-running manager for the offering.
• The company has granted the underwriters a 30-day option to purchase up to 300,000 additional shares to cover over-allotments.
• The company will effect a 1-for-11.9 reverse stock split prior to the effective date of the registration statement.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company highlights its growth strategy, premier retail partnerships, and a clinically-tested product, it also acknowledges a working capital deficit, decreased revenue and earnings for the recent period, and dependence on a few key customers. The potential for future growth is balanced by existing financial challenges and market competition.

Positives

• The company has a scalable and flexible asset-light model to support growth.
• The company has established distribution relationships with premier retail partners.
• FOCUSfactor is supported by an independent clinical study.
• The brain health segment is slated to grow at 8% per year in the United States and 13% per year globally, according to Grand View Research.
• The company has expanded internationally into Canada and the UK and anticipates being in Taiwan and Mexico in the second quarter of 2025 and in Australia and Asia in the first quarter of 2026.
• The company's EBITDA improved significantly in 2023 due to increased revenue, distribution, and non-recurring items in 2022.

Negatives

• The company had a working capital deficit of $3.8 million as of June 30, 2024.
• Net revenue for the six months ended June 30, 2024, decreased by 7.0% compared to the same period in 2023.
• The company's sales growth is dependent upon maintaining relationships with a small number of existing large customers.
• The company's capital structure following the acquisitions of its key brands in 2015 has been highly levered.
• The company's net income and EBITDA decreased by 50% and 18%, respectively, for the six months ended June 30, 2024, compared to the same period in the prior fiscal year.

Risks

• The company operates in a highly competitive industry.
• The company's failure to respond to changing consumer preferences could harm its relationship with customers.
• The company's sales growth is dependent on maintaining relationships with a small number of large retailers.
• The company's outside suppliers and manufacturers may fail to supply products in sufficient quantities.
• Adverse or negative publicity could cause the company's business to suffer.
• The company may not be able to successfully execute on its strategic initiatives.
• The company may experience product recalls, withdrawals, or seizures.
• The company is subject to numerous laws and regulations that apply to the manufacturing and sale of nutritional supplements.
• The company's existing indebtedness may adversely affect its ability to obtain additional funds.
• The company may need to raise additional capital in the future, and its failure to do so could restrict its operations.

Future Outlook

The company intends to use the net proceeds of this offering for general corporate purposes and to accelerate the growth of its FOCUSfactor supplements and energy RTD products. The company plans to expand into new markets, including Taiwan, Mexico, Australia, and Asia.

Management Comments

• Management believes that cash provided by sales of our products will be sufficient to meet these obligations as they come due, or that we may refinance our indebtedness to extend the term.
• Managements philosophy is to acquire promising brands that fit within our health, beauty and lifestyle offerings, and apply our marketing and distribution strategies to develop brands to their full potential.

Industry Context

The global nutritional supplement market is expected to grow at a CAGR of approximately 9.3% from 2018 to 2028. The brain health supplement market was estimated to be $8.6 billion in 2022 and is expected to grow at a CAGR of 13.3% from 2023 to 2030. The weight management and wellbeing market was estimated to be an $11.3 billion global market in 2022, with forecasted growth of 4.0% annually from 2023 to 2032.

Comparison to Industry Standards

• Celsius and Beyond Raw offer dual-benefit products that deliver fat burning plus energy.
• C4 Smart Energy and FocusAid deliver focus plus energy.
• Competitors like Red Bull and Monster delivered conventional energy, then the category offered more performance energy products with added vitamins and amino acids in products such as Reign and C4 Performance to products with more natural energy characteristics and then to the dual-benefit energy products that we see today.

Legal Proceedings

• In August 2022, the company filed a lawsuit in the Superior Court of Maine against one of its contract manufacturers, which was settled during December 2023, resulting in a net gain to the company of $2,235,986 and a loan payable of $5,450,000.
• On July 28, 2023, L.O.D.C. Group asserted claims of over $1,000,000 against the company for breach of contract, which was settled during April 2024.

Related Party Transactions

• The company has a Sales and Marketing Consultant and Distribution Agreement with Kenek Brands Inc., a company owned by Jack Ross, the Chief Executive Officer.
• The company has an Amended and Restated Loan Agreement with Knight Therapeutics (Barbados) Inc., an affiliate of an owner of greater than 10% of the company's outstanding common stock.
• The company has distribution agreements with Knight Therapeutics, Inc. and Knight Therapeutics International S.A. for the distribution rights of FOCUSfactor, Hand MD, and Flat Tummy in various regions.
• The company has transactions with BoomBod Ltd., a related party 100% indirectly owned by Jack Ross, the Chief Executive Officer.
• The company has transactions with Gowan Properties Inc., a related party 100% indirectly owned by Jack Ross, the Chief Executive Officer.

Stakeholder Impact

• The public offering will provide capital for the company to invest in growth initiatives, potentially benefiting shareholders.
• The company's performance and strategic decisions will impact employees, customers, and suppliers.
• The company's ability to meet its debt obligations will affect its creditors.

Next Steps

• The company anticipates a coordinated expansion of its advertising strategy towards the end of 2024.
• The company plans to introduce new graphics for the FOCUSfactor line in the third quarter of 2024.
• The company plans on introducing new complementary products to the Flat Tummy line-up in the fourth quarter of 2024.
• The company plans to introduce an additional FOCUSfactor supplement for Taiwan, RTDs for the UK and focus and energy coffee for the United States in 2025.
• The company plans to enter the Taiwan and Mexico markets in the second quarter of 2025.
• The company plans to expand its brands into Australia and Asian markets in 2026.

Key Dates

Keywords

FOCUSfactor, Flat Tummy, IPO, Nasdaq, Public Offering, Consumer Health, Nutritional Supplements, EBITDA, Net Revenue, SNYR